Business Wire

Eiffage Selected FINALCAD As a Strategic Partner to Accelerate Digital Transformation of Its Construction Sites

Del

Eiffage selected FINALCAD as a strategic partner to accelerate the digital transformation of the construction sites of the Group, in an open innovation approach.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170619005968/en/

Benoit de Ruffray, Chairman and CEO, Eiffage with FINALCAD co-founders Jimmy Louchart, Joffroy Louch ...

Benoit de Ruffray, Chairman and CEO, Eiffage with FINALCAD co-founders Jimmy Louchart, Joffroy Louchart and David Vauthrin. Photo credit : Alejandra Gomez. (Photo: Business Wire)

The digital transformation of the construction industry has turned into a strategic dimension for the performance of companies in this space. It is a driver of , productivity gains and quality improvement for the construction and infrastructure projects.

Aware of the quick changes happening in the digitalisation ecosystem of the construction industry, Eiffage has taken a stance to adopt a partnership approach with innovative start-ups. Such partnerships provide the Group with a better agility and direct access to the expertise of these innovative companies, often several years worth of investment in Research & Development.

“We selected FINALCAD because their approach to the field is different from other players in the market, and their product has received positive feedback from users on the field. This strong partnership is based on an open, two-sided innovation model. FINALCAD needs Eiffage to grow even stronger, and Eiffage needs FINALCAD to accelerate” said Benoît de Ruffray, Chairman and CEO, Eiffage.

The initial objective of the Group was to digitise two thirds of Eiffage Construction projects with FINALCAD by 2018. This objective has already been reached to date, demonstrating very strong adoption by the field, beyond expectations. Other branches of the Group have also started their digitisation with FINALCAD.

“FINALCAD was successfully used on projects of the Eiffage Group since 2012, but was limited to a project-based approach. From now on, we will accompany Eiffage in an enterprise-wide digital transformation, opening new perspectives in analytics for driving activity performance” said Jimmy Louchart, co-founder and CEO, FINALCAD. “From our point of view, the stance that Eiffage has taken with this partnership to accelerate their digital transformation is a clear demonstration of being an agile player and forerunner in France and in the world.”

About Eiffage

Eiffage is one of Europe's leading construction and concessions companies. The Group's activities are organised on the basis of the following business lines: construction, real estate, regional development, civil engineering, metal, roads, energy and concessions. Thanks to the experience of more than 63,000 employees, Eiffage generated revenues of €14 billion in 2016, including nearly 20% outside France.

About FINALCAD

FINALCAD is a global leader in field mobile apps and predictive analytics for construction, infrastructure, energy and concessions. It helps contractors, developers, architects and field operators with quality control, defect management and progress monitoring, during construction and facility management. Since 2011, FINALCAD has been delivering more than 15,000 projects in 35 countries, and has secured over $22 million in funding from investors including Serena Capital, Aster Capital, and CapHorn Invest.

Contact information

Eiffage
Sophie Mairé
+ 33 (0) 1 71 59 10 62
sophie.maire@eiffage.com
or
FINALCAD
Aurélien Blaha
+33 (0) 6 23 99 92 99
aurelien@finalcad.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 08:43Pressemelding

LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova

Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 08:29Pressemelding

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em

Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 08:00Pressemelding

Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio

Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 08:00Pressemelding

(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p

Record Attendance at Japan Content Showcase 2017!20.11.2017 03:00Pressemelding

Japan Content Showcase 2017 was held October 23-26 at Ikebukuro Sunshine City and the Shibuya Excel Hotel Tokyu. A record 19,549 people participated in sales meetings, excluding the TIMM Showcase Live. Other new records this year were 371 exhibiting groups from 27 countries and regions and 1,549 buyers from 48 countries and regions. There was a significant increase in overseas buyers this year, the 1022 foreign registrations representing an increase of more than 10% over last year. The number of non-Japanese Asian buyers increased by 6%, North Americans by 13%, South Americans by 44%, and Europeans by 49%. The number of Middle Eastern buyers doubled, and there were more than five times the number of Russian buyers as last year. French buyers were up 70%, Italians 60%, British 75%, and Germans 50%. Business matching was a new service offered by the organizers this year. Meeti

Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01Pressemelding

Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom